Impacto económico estimado de las vacunas en 73 países con ingresos bajos y medios, 2001-2020

Translated title of the contribution: Estimated economic impact of vaccinations in 73 low- and middleincome countries, 2001–2020

Sachiko Ozawa, Samantha Clark, Allison Portnoy, Simrun Grewal, Meghan L. Stack, Anushua Sinha, Andrew Mirelman, Heather Franklin, Ingrid K. Friberg, Yvonne Tam, Neff Walker, Andrew Clark, Matthew Joseph Ferrari, Chutima Suraratdecha, Steven Sweet, Sue J. Goldie, Tini Garske, Michelle Li, Peter M. Hansen, Hope L. Johnson & 1 others Damian Walker

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective To estimate the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. Methods We used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In comparison with no vaccination, we modelled the costs – expressed in 2010 United States dollars (US$) – of averted treatment, transportation costs, productivity losses of caregivers and productivity losses due to disability and death. We used the value-of-a-life-year method to estimate the broader economic and social value of living longer, in better health, as a result of immunization. Findings We estimated that, in the 73 countries, vaccinations given between 2001 and 2020 will avert over 20 million deaths and save US$ 350 billion in cost of illness. The deaths and disability prevented by vaccinations given during the two decades will result in estimated lifelong productivity gains totalling US$ 330 billion and US$ 9 billion, respectively. Over the lifetimes of the vaccinated cohorts, the same vaccinations will save an estimated US$ 5 billion in treatment costs. The broader economic and social value of these vaccinations is estimated at US$ 820 billion. Conclusion By preventing significant costs and potentially increasing economic productivity among some of the world’s poorest countries, the impact of immunization goes well beyond health.

Original languageSpanish
Pages (from-to)629-638
Number of pages10
JournalBulletin of the World Health Organization
Volume95
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Vaccination
Economics
Social Values
Health Care Costs
Immunization
Serogroup A Neisseria meningitidis
Health
Vaccines
Japanese Encephalitis
Value of Life
Yellow Fever
Costs and Cost Analysis
Haemophilus influenzae type b
Cost of Illness
Rubella
Rotavirus
Measles
Streptococcus pneumoniae
Hepatitis B
Caregivers

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

Ozawa, Sachiko ; Clark, Samantha ; Portnoy, Allison ; Grewal, Simrun ; Stack, Meghan L. ; Sinha, Anushua ; Mirelman, Andrew ; Franklin, Heather ; Friberg, Ingrid K. ; Tam, Yvonne ; Walker, Neff ; Clark, Andrew ; Ferrari, Matthew Joseph ; Suraratdecha, Chutima ; Sweet, Steven ; Goldie, Sue J. ; Garske, Tini ; Li, Michelle ; Hansen, Peter M. ; Johnson, Hope L. ; Walker, Damian. / Impacto económico estimado de las vacunas en 73 países con ingresos bajos y medios, 2001-2020. In: Bulletin of the World Health Organization. 2017 ; Vol. 95, No. 9. pp. 629-638.
@article{f8a4a4ace39a49c8b5efbaa389a9acad,
title = "Impacto econ{\'o}mico estimado de las vacunas en 73 pa{\'i}ses con ingresos bajos y medios, 2001-2020",
abstract = "Objective To estimate the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. Methods We used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In comparison with no vaccination, we modelled the costs – expressed in 2010 United States dollars (US$) – of averted treatment, transportation costs, productivity losses of caregivers and productivity losses due to disability and death. We used the value-of-a-life-year method to estimate the broader economic and social value of living longer, in better health, as a result of immunization. Findings We estimated that, in the 73 countries, vaccinations given between 2001 and 2020 will avert over 20 million deaths and save US$ 350 billion in cost of illness. The deaths and disability prevented by vaccinations given during the two decades will result in estimated lifelong productivity gains totalling US$ 330 billion and US$ 9 billion, respectively. Over the lifetimes of the vaccinated cohorts, the same vaccinations will save an estimated US$ 5 billion in treatment costs. The broader economic and social value of these vaccinations is estimated at US$ 820 billion. Conclusion By preventing significant costs and potentially increasing economic productivity among some of the world’s poorest countries, the impact of immunization goes well beyond health.",
author = "Sachiko Ozawa and Samantha Clark and Allison Portnoy and Simrun Grewal and Stack, {Meghan L.} and Anushua Sinha and Andrew Mirelman and Heather Franklin and Friberg, {Ingrid K.} and Yvonne Tam and Neff Walker and Andrew Clark and Ferrari, {Matthew Joseph} and Chutima Suraratdecha and Steven Sweet and Goldie, {Sue J.} and Tini Garske and Michelle Li and Hansen, {Peter M.} and Johnson, {Hope L.} and Damian Walker",
year = "2017",
month = "9",
day = "1",
doi = "10.2471/BLT.16.178475",
language = "Spanish",
volume = "95",
pages = "629--638",
journal = "Bulletin of the World Health Organization",
issn = "0042-9686",
publisher = "World Health Organization",
number = "9",

}

Ozawa, S, Clark, S, Portnoy, A, Grewal, S, Stack, ML, Sinha, A, Mirelman, A, Franklin, H, Friberg, IK, Tam, Y, Walker, N, Clark, A, Ferrari, MJ, Suraratdecha, C, Sweet, S, Goldie, SJ, Garske, T, Li, M, Hansen, PM, Johnson, HL & Walker, D 2017, 'Impacto económico estimado de las vacunas en 73 países con ingresos bajos y medios, 2001-2020', Bulletin of the World Health Organization, vol. 95, no. 9, pp. 629-638. https://doi.org/10.2471/BLT.16.178475

Impacto económico estimado de las vacunas en 73 países con ingresos bajos y medios, 2001-2020. / Ozawa, Sachiko; Clark, Samantha; Portnoy, Allison; Grewal, Simrun; Stack, Meghan L.; Sinha, Anushua; Mirelman, Andrew; Franklin, Heather; Friberg, Ingrid K.; Tam, Yvonne; Walker, Neff; Clark, Andrew; Ferrari, Matthew Joseph; Suraratdecha, Chutima; Sweet, Steven; Goldie, Sue J.; Garske, Tini; Li, Michelle; Hansen, Peter M.; Johnson, Hope L.; Walker, Damian.

In: Bulletin of the World Health Organization, Vol. 95, No. 9, 01.09.2017, p. 629-638.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impacto económico estimado de las vacunas en 73 países con ingresos bajos y medios, 2001-2020

AU - Ozawa, Sachiko

AU - Clark, Samantha

AU - Portnoy, Allison

AU - Grewal, Simrun

AU - Stack, Meghan L.

AU - Sinha, Anushua

AU - Mirelman, Andrew

AU - Franklin, Heather

AU - Friberg, Ingrid K.

AU - Tam, Yvonne

AU - Walker, Neff

AU - Clark, Andrew

AU - Ferrari, Matthew Joseph

AU - Suraratdecha, Chutima

AU - Sweet, Steven

AU - Goldie, Sue J.

AU - Garske, Tini

AU - Li, Michelle

AU - Hansen, Peter M.

AU - Johnson, Hope L.

AU - Walker, Damian

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objective To estimate the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. Methods We used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In comparison with no vaccination, we modelled the costs – expressed in 2010 United States dollars (US$) – of averted treatment, transportation costs, productivity losses of caregivers and productivity losses due to disability and death. We used the value-of-a-life-year method to estimate the broader economic and social value of living longer, in better health, as a result of immunization. Findings We estimated that, in the 73 countries, vaccinations given between 2001 and 2020 will avert over 20 million deaths and save US$ 350 billion in cost of illness. The deaths and disability prevented by vaccinations given during the two decades will result in estimated lifelong productivity gains totalling US$ 330 billion and US$ 9 billion, respectively. Over the lifetimes of the vaccinated cohorts, the same vaccinations will save an estimated US$ 5 billion in treatment costs. The broader economic and social value of these vaccinations is estimated at US$ 820 billion. Conclusion By preventing significant costs and potentially increasing economic productivity among some of the world’s poorest countries, the impact of immunization goes well beyond health.

AB - Objective To estimate the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. Methods We used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In comparison with no vaccination, we modelled the costs – expressed in 2010 United States dollars (US$) – of averted treatment, transportation costs, productivity losses of caregivers and productivity losses due to disability and death. We used the value-of-a-life-year method to estimate the broader economic and social value of living longer, in better health, as a result of immunization. Findings We estimated that, in the 73 countries, vaccinations given between 2001 and 2020 will avert over 20 million deaths and save US$ 350 billion in cost of illness. The deaths and disability prevented by vaccinations given during the two decades will result in estimated lifelong productivity gains totalling US$ 330 billion and US$ 9 billion, respectively. Over the lifetimes of the vaccinated cohorts, the same vaccinations will save an estimated US$ 5 billion in treatment costs. The broader economic and social value of these vaccinations is estimated at US$ 820 billion. Conclusion By preventing significant costs and potentially increasing economic productivity among some of the world’s poorest countries, the impact of immunization goes well beyond health.

UR - http://www.scopus.com/inward/record.url?scp=85028774715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028774715&partnerID=8YFLogxK

U2 - 10.2471/BLT.16.178475

DO - 10.2471/BLT.16.178475

M3 - Article

VL - 95

SP - 629

EP - 638

JO - Bulletin of the World Health Organization

JF - Bulletin of the World Health Organization

SN - 0042-9686

IS - 9

ER -